FR3057266B1 - Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression - Google Patents

Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression Download PDF

Info

Publication number
FR3057266B1
FR3057266B1 FR1754127A FR1754127A FR3057266B1 FR 3057266 B1 FR3057266 B1 FR 3057266B1 FR 1754127 A FR1754127 A FR 1754127A FR 1754127 A FR1754127 A FR 1754127A FR 3057266 B1 FR3057266 B1 FR 3057266B1
Authority
FR
France
Prior art keywords
ntsr3
treatment
depression
peptides derived
propeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1754127A
Other languages
English (en)
Other versions
FR3057266A1 (fr
Inventor
Jean Mazella
Marc Borsotto
Catherine Heurteaux
Alaeddine Djillani
Sebastien Moreno
Mariel Pietri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Nice Sophia Antipolis UNSA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Nice Sophia Antipolis UNSA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1659781A external-priority patent/FR3057267A1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Nice Sophia Antipolis UNSA filed Critical Centre National de la Recherche Scientifique CNRS
Priority to PL17794365.1T priority Critical patent/PL3526244T3/pl
Priority to HRP20231567TT priority patent/HRP20231567T1/hr
Priority to PCT/FR2017/052788 priority patent/WO2018069641A1/fr
Priority to EP17794365.1A priority patent/EP3526244B1/fr
Priority to JP2019518949A priority patent/JP7034151B2/ja
Priority to FIEP17794365.1T priority patent/FI3526244T3/en
Priority to US16/340,832 priority patent/US11220527B2/en
Priority to ES17794365T priority patent/ES2965080T3/es
Priority to PT177943651T priority patent/PT3526244T/pt
Priority to CA3039273A priority patent/CA3039273A1/fr
Priority to DK17794365.1T priority patent/DK3526244T5/da
Publication of FR3057266A1 publication Critical patent/FR3057266A1/fr
Publication of FR3057266B1 publication Critical patent/FR3057266B1/fr
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouveaux peptides dérivés du récepteur de la neurotensine 3 (NTSR3), et à leur utilisation notamment dans le traitement de différentes pathologies, en particulier de la dépression.
FR1754127A 2016-10-11 2017-05-11 Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression Active FR3057266B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US16/340,832 US11220527B2 (en) 2016-10-11 2017-10-11 Peptides derived from the propeptide NTSR3 and their use in the treatment of depression
ES17794365T ES2965080T3 (es) 2016-10-11 2017-10-11 Péptidos derivados del propéptido NTSR3 y su uso en el tratamiento de la depresión
PCT/FR2017/052788 WO2018069641A1 (fr) 2016-10-11 2017-10-11 Peptides dérivés du propeptide ntsr3 et leur utilisation dans le traitement de la dépression
EP17794365.1A EP3526244B1 (fr) 2016-10-11 2017-10-11 Peptides dérivés du propeptide ntsr3 et leur utilisation dans le traitement de la dépression
JP2019518949A JP7034151B2 (ja) 2016-10-11 2017-10-11 プロペプチドｎｔｓｒ３に由来するペプチド、及びうつ病の治療におけるその使用
FIEP17794365.1T FI3526244T3 (en) 2016-10-11 2017-10-11 PEPTIDES DERIVED FROM NTSR3 PROPEPTIDE AND THEIR USE IN THE TREATMENT OF DEPRESSION
PL17794365.1T PL3526244T3 (pl) 2016-10-11 2017-10-11 Peptydy pochodzące z propeptydu ntsr3 i ich zastosowanie w leczeniu depresji
HRP20231567TT HRP20231567T1 (hr) 2016-10-11 2017-10-11 Peptidi izvedeni iz propeptida ntsr3 i njihova uporaba u liječenju depresije
PT177943651T PT3526244T (pt) 2016-10-11 2017-10-11 Péptidos derivados do propéptido ntsr3 e a sua utilização no tratamento da depressão
CA3039273A CA3039273A1 (fr) 2016-10-11 2017-10-11 Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression
DK17794365.1T DK3526244T5 (da) 2016-10-11 2017-10-11 Peptider afledt af propeptidet ntsr3 og deres anvendelse ved behandling af depression

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1659781A FR3057267A1 (fr) 2016-10-11 2016-10-11 Procede de diagnostic/determination de l'efficacite de traitement de la depression
FR1659781 2016-10-11
FR1752162 2017-03-16
FR1752162A FR3057268B1 (fr) 2016-10-11 2017-03-16 Procede de diagnostic/determination de l'efficacite de traitement de la depression

Publications (2)

Publication Number Publication Date
FR3057266A1 FR3057266A1 (fr) 2018-04-13
FR3057266B1 true FR3057266B1 (fr) 2021-05-21

Family

ID=60262946

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1754127A Active FR3057266B1 (fr) 2016-10-11 2017-05-11 Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression

Country Status (1)

Country Link
FR (1) FR3057266B1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8066997B2 (en) * 2002-12-20 2011-11-29 Anders Nykjaer Modulation of activity of neurotrophins
EP2077278A1 (fr) * 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
US20120322060A1 (en) * 2011-04-13 2012-12-20 Centre National De Le Recherche Scientifique - Cnrs - Diagnosis and monitoring treatment of psychiatric diseases with spadin and related methods
WO2015110915A2 (fr) * 2014-01-27 2015-07-30 Medincell Analogues rétro-inverso de spadine à effets antidépresseurs accrus

Also Published As

Publication number Publication date
FR3057266A1 (fr) 2018-04-13

Similar Documents

Publication Publication Date Title
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
EA201792583A1 (ru) Способы и композиции для ингибирования взаимодействия менина с белками mll
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA202191632A1 (ru) Ахромосомные динамические активные системы
EA201992546A1 (ru) Средства на основе антител к cd33
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
PH12019550076A1 (en) SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
BR112016026950A2 (pt) composições de rnai para angiotensinogênio (agt) e métodos de uso das mesmas
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
GEP20217252B (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
CL2018000622A1 (es) Acetamida tienodiazepinas de triazol y sus usos relacionados.
EA202092692A1 (ru) Аналоги рапамицина и их применения
MX2020007628A (es) Composiciones y metodos de uso.
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
EA201992883A1 (ru) АНТИТЕЛА К TrkB

Legal Events

Date Code Title Description
PLSC Publication of the preliminary search report

Effective date: 20180413

PLFP Fee payment

Year of fee payment: 2

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8